Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 4401–4450 of 18411
On July 15, 2024, Steven Rudofsky notified Idaho Copper Corporation (the “Company”) of his resignation from his position as Chief Executive Officer and President of the Company, effective immediately.
Effective July 15, 2024, Andrew Brodkey, the Company’s Chief Operating Officer and Secretary was appointed as Chief Executive Officer and President of the Company, by unanimous written consent of the members of the Board
On July 12, 2024, Intellicheck, Inc., a Delaware corporation (the “Company”), and Jeffrey Ishmael, the Company’s Chief Financial Officer and Chief Operating Officer, entered into a separation agreement (the “Agreement”), pursuant to which Mr. Ishmael’s last date of employment with the Company will be August 31, 2024 (the “Separation Date”).
On July 18, 2024, BeiGene, Ltd. (the “Company”) announced the appointment of Aaron Rosenberg as the Chief Financial Officer (“CFO”) and the principal financial officer of the Company, effective as of July 22, 2024 (the “Effective Date”).
On July 17, 2024, Julia Wang, the Company’s current CFO, resigned as CFO effective July 19, 2024.
On July 5, 2024, the Board accepted the resignation of Mr. Reali, and on the same day appointed Mr. Ciavarella as the Interim Chief Financial Officer to assume the responsibilities as the Company’s principal accounting officer until a suitable replacement is found.
On July 5, 2024, the Board accepted the resignation of Mr. Reali
Christian Rothe has been named Senior Vice President and Chief Financial Officer of the Company, effective August 19, 2024.
Mr. Rothe succeeds Nicholas Gangestad, who has served as Senior Vice President and Chief Financial Officer of the Company since March 2021.
Effective as of July 12, 2024, Eric Wintemute concluded his role as Chief Executive Officer of American Vanguard Corporation (the “Company”).
Mr. Donnelly has also been designated as, and assumed the duties of, the Company’s Acting Chief Executive Officer and acting principal executive officer as of July 12, 2024.
In connection with Mr. Caudill’s appointment as interim Chief Executive Officer, on July 16, 2024, the Company entered into a consulting agreement (the “Consulting Agreement”) with Mr. Caudill.
As previously disclosed in the Initial Form 8-K, in connection with his resignation as President and Chief Executive Officer of the Company, Mr. Fehrman will forfeit all of his unvested restricted stock units and cash incentive awards and repay the $2.0 million signing bonus paid to him upon commencement of his employment with the Company.
appointed Joel D. Anderson to succeed R. Michael Mohan, interim Chief Executive Officer, as the Chief Executive Officer of the Company
appointed Joel D. Anderson to succeed R. Michael Mohan, interim Chief Executive Officer, as the Chief Executive Officer of the Company (the “CEO Succession”), effective as of July 29, 2024
On July 15, 2024, the Board of Directors of Emmaus Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” or the “company”) appointed Willis Lee as our Chief Executive Officer and eliminated the former offices of interim Co-President.
On July 15, 2024, Remi Barbier, President and Chief Executive Officer of Cassava Sciences, Inc. (the “ Company ” or “ Cassava ”) resigned from the Company, effective as of September 13, 2024
by mutual agreement, James Stanker resigned as Chief Financial Officer of the Company, effective July 15, 2024.
announced the appointment of Mr. Russell Skibsted, Effective July 16, 2024 as its Chief Financial Officer.
Effective on July 15, 2024, Mr. Nelson Cabatuan resigned from his position as the Company’s Chief Financial Officer in order to focus his attention on corporate finance and strategic industry relationships for Lexaria as its Chief Strategic Financial Advisor.
on July 11, 2024, Tracey T. Travis, Executive Vice President and Chief Financial Officer of The Estée Lauder Companies Inc. (the “Company”), notified the Company of her decision to retire effective June 30, 2025.
On July 11, 2024, Paul M. Pickett notified Old Point Financial Corporation (the “Company”) of his decision to resign as Chief Financial Officer & Senior Vice President/Finance and principal financial and accounting officer of the Company and as Chief Financial Officer & Executive Vice President of The Old Point National Bank of Phoebus (the “Bank”), the Company’s wholly owned national bank subsidiary.
Cathy W. Liles, age 59, the Company’s Chief Accounting Officer & Senior Vice President, has been named Interim Chief Financial Officer.
On July 15, 2024, the Board appointed Mr. Kenneth R. Bull, the Chief Operating Officer of the Company, to also serve as the Company’s President and Chief Executive Officer on an interim basis while the Company conducts a search for Mr. Anderson’s permanent replacement.
On July 15, 2024, Joel D. Anderson, President and Chief Executive Officer of Five Below, Inc. (the “Company”), notified the Company’s Board of Directors (the “Board”) that he was resigning as President and Chief Executive Officer and a member of the Board effective immediately.
She was promoted to CEO, CFO and Chairman of the Board as a part of their succession plan, which was created due to the failing health of Mr. John Poss.
Mr. Poss had battled through serious health issues and had served the company very well since 2015. Fortunately, Mr. Poss had spent years preparing Dr. Small-Howard for her expanded role as CEO, CFO and Chairman, which roles fell to her upon the passing of Mr. Poss on July 10, 2024.
On June 15, 2024, Jeffery Cauble, the Chief Financial Officer of ThermoGenesis Holdings, Inc. (the “Company”), resigned as an employee and officer of the Company.
On July 16, 2024, the Board of Directors (the “Board”) of ChromaDex Corporation (the “Company” or “ChromaDex”) appointed James Lee, the Company’s current Controller, as the Company’s Interim Chief Financial Officer and Interim Principal Accounting Officer, effective as of July 13, 2024.
As previously disclosed, Brianna Gerber resigned from her roles as the Company’s Chief Financial Officer and Principal Accounting Officer effective July 12, 2024.
Richard Hume, the Company’s current President and Chief Executive Officer, will retire from the Company but remain on the Company’s Board of Directors.
effective September 1, 2024, Patrick Zammit, the Company’s Executive Vice President, Chief Operating Officer, will be appointed President and Chief Executive Officer
Terry-Ann Burrell notified Beam Therapeutics Inc. (the “Company”) of her decision to resign as Chief Financial Officer and Treasurer of the Company, effective August 9, 2024, to pursue other opportunities.
On July 15, 2024, the Company announced the appointment of R. David Rosato as its Chief Financial Officer. Mr. Rosato is expected to commence his role with the Company effective August 1, 2024.
James B. Fitzgerald, the principal financial officer of the Company, notified the Company’s Chief Executive Officer and the Audit Committee of its Board of Directors on April 24, 2024, that he planned to transition from his roles as Chief Financial Officer, Chief Administrative Officer and Treasurer of the Company effective upon the appointment and commencement of employment of his successor.
Jean-Marc Gilson was appointed as the President, Chief Executive Officer and Director of the General Partner.
Jean-Marc Gilson was appointed as the President and Chief Executive Officer of the Company.
effective upon the previously announced retirement of Glenn MacInnes from his position as Executive Vice President and Chief Financial Officer of the Company and the Bank, which is expected in August 2024.
The Board of Directors also appointed Mr. Holland as the Chief Financial Officer of the Company and the Bank, effective upon the previously announced retirement of Glenn MacInnes from his position as Executive Vice President and Chief Financial Officer of the Company and the Bank, which is expected in August 2024.
following an approximately 60-day transition with Veeva board member and interim CFO, Tim Cabral.
Brian Van Wagener will become Veeva’s chief financial officer (“CFO”) following an approximately 60-day transition with Veeva board member and interim CFO, Tim Cabral.
On July 11, 2024, the Company and Robin Ross entered into an employment agreement (the “Ross Employment Agreement”), effective as of July 11, 2024 (the “Ross Employment Agreement Effective Date”), pursuant to which Mr. Ross will serve as Chief Executive Officer of the Company, replacing Mr. Peterson, and will also continue to serve as the Chairman of the Board.
On July 9, 2024, Michael L. Peterson delivered to the Board of Directors (“Board”) of Trio Petroleum Corp. (the “Company”) a notice of his resignation as the Company’s Chief Executive Officer and a member of the Board, effective on July 11, 2024 (the “Resignation Effective Date”).
Mr. Hisey, the current interim CEO of the Company, was reappointed as Chief Financial Officer (the “CFO”).
On July 15, 2024, Envista Holdings Corporation (the “Company”) announced that it has appointed Eric Hammes as the Senior Vice President and Chief Financial Officer of the Company, with such appointment to be effective as of August 8, 2024.
the Board appointed Jay Jennings, the Company’s Chief Financial Officer, to serve as the Acting Chief Executive Officer of the Company effective upon the termination of Mr. Beck as Chief Executive Officer.
On July 10, 2024, Martin Beck submitted a letter of resignation to the Chairman of the Board of Directors (the “Board”) of UpHealth, Inc. (the “Company”) from his positions as the Chief Executive Officer of the Company and all subsidiaries of the Company for which he serves as Chief Executive Officer.
the Board appointed Mr. Honjian as President/CEO and CFO and as Secretary
the Board appointed Mr. Honjian as President/CEO and CFO and as Secretary
the Company’s President and Chief Executive Officer (“CEO”) Kevin P. Riley will be retiring and a search has been initiated for his successor.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.